Aim To investigate interleukin 6 (IL-6) values depending on duration of diabetes mellitus (DM) and evaluate possible correlation with diabetic polyneuropathy. Methods The research study included 90 patients with DM divided into three groups (30 patients each) according to the duration of DM: group A – patients who had DM for less than 10 years, group B - duration of DM was 10 to 20 years, and group C - patients with DM over 20 years. Control group (K) included 30 healthy participants. Results IL-6 was significantly higher in the healthy control group, 180.318 pg/mL±94.18, than in group A, 47.23pg/ml±34.8, group B, 43.31pg/ml±33.17, and group C, 70.39 pg/ml±59.26 (p=0.0001). All groups had significantly different values of IL-6 between each other (p=0.0001). Level of IL-6 was in correlation with diabetic polyneuropathy in the group A (the youngest participants) (p=0.0001). In other groups there was no significant correlation between IL-6 and diabetic polyneuropathy. Conclusion The level of IL-6 was in correlation with neuropathy among younger patients. A higher level of IL-6 in the control group than in diabetic groups is a sign of stronger inflammatory response among younger and healthy people than in patients with DM.
Russell J, Zilliox L. Diabetic neuropathies. Continuum. Minneap Minn). 2014;1226–40.
2.
Volmer-Thole M, Lobmann R. Neuropathy and diabetic foot syndrome. Int J Mol Sci. 2016;917.
3.
Mallet ML, Hadjivassiliou M. Ptolemaios Georgios arrigiannis, Panagiotis Zis. The role of oxidative stress in peripheral neuropathy. J Mol Neurosci. 2020;1009–17.
4.
Morali G, Salamone P, Casale F, Fuda G, Cugnasco P, Carosi C, et al. NADPH oxidase 2 (NOX2) enzyme activation in patients with Chronic Inflammatory demyelinating Polyneuropathy. Eur J Neurol. 2016;958–63.
5.
Villegas-Rivera G, Román-Pintos M, L, Cardona-Muñoz G, Arias-Carvajal E, O, et al. Effects of zetimibe/simvastatin and rosuvastatin on oxidative stress in diabetic neuropathy: A randomized, double-blind. 2015;75–62.
6.
Klermm C, Ch B, Kruchten A, Niemann S, Loffler B, Peters G, et al. Mitogen activated protein kinases (MAPKs) regulate IL-6 over-production during concomitant influenza virus and staphylococcus aureus infection. Nature. 2017;424–57.
7.
Bastard J, Jardel C, Delattre J, Hainque B, Bruckert E, Oberlin F. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation. 1999;2221–2.
8.
Febbraio M, Pedersen B. Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Ex Sport Sci. 2005;114–9.
9.
Kristiansen O, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005;
10.
Louis E, Raue U, Yang Y, Jemiolo B, Trappe S. Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle. J Appl Physiol. 1985;1744–51.
11.
Ziegler D, Bucholz S, Sohr C, Norrouc Z. Oxidative stress predicts peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients. Acta Diabetol. 2015;65–72.
12.
Cho N, Shaw J, J, Karuranga S, Huang S, Y, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diab Res and Clin Practice. 2018;271–81.
13.
Vacante M, Malaguarnera M, Motta M. Revision of the ADA-classification of diabetes mellitus type 2 (DMT2): the importance of maturity onset diabetes (MOD), and senile diabetes (DS). Arch Gerontol Res. 2018;113–9.
14.
Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;62–9.
15.
Tesfaye S, Boulton A, Dyck P, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;(10):2285–93.
16.
Herman W, Pop-Busui R, Barffett B, Martin C, Cleary P, Albers J. Use of the Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012;937–44.
17.
Park J, Kim D. The necessity of the simple tests for diabetic peripheral neuropathy in type 2 Diabetes Mellitus patients without neuropathic symptoms in clinical practice. J Diabetes Metab J. 2018;442–6.
18.
Kaplan Y, Kurt S, Ünaldi K, Erkorkmaz H, Ü. Risk factors for diabetic polyneuropathy. Noro Psikiyatr Ars. 2014;11–4.
19.
Rashad N, El-Shabrawy R, Sabry H, Fathy H, Said D, Yousef M. Interleukin-6 and hs-CRP as early diagnostic biomarkers for obesity-related peripheral polyneuropathy in non-diabetic patients. Egypt J Immunol. 2018;153–65.
20.
Tuttolomondo A, Placa L, S, Raimondo D, D, Ch B, et al. Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity. Cardiovasc Diabetol. 2010;50.
21.
Skyler J, Bakris G, Bonifacio E, Darsow T, Eckel R, Groop L, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017;241–55.
22.
Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules. 2020;
23.
Bornstein S, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld A, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;546–50.
24.
Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, et al. Oxidative stress: harms and benefits for human health. Oxid Med Cell Longev. 2017;8416763.
25.
Akiboye F, Rayman G. Management of Hyperglycemia and diabetes in orthopedic surgery. Curr Diab Rep. 2017;13.
26.
Magrinelli F, Ch B, Romano M, Ruggero S, Toffanin E, Triolo G, et al. The association between serum cytokines and damage to large and small nerve fibers in diabetic peripheral neuropathy. J Diabetes Res. 2015;547834.
27.
Korkmaz P, Koçak H, Onbaşı K, Biçici P, Özmen A, Uyar C, et al. The Role of serum procalcitonin, interleukin-6, and fibrinogen levels in differential diagnosis of diabetic foot ulcer infection. J Diabetes Res. 2018;7104352.
28.
Obradovic S, Begic E, Jankovic S, Romanovic R, Djenic N, Dzudovic B, et al. Association of PC and AT levels in the early phase of STEMI treated with pPCI with LV systolic function and 6-month MACE. Acta Clin Belg. 2020;1–7.
29.
Cox A, Sagot Y, Hedou G, Grek C, Wilkes T, Vinik A, et al. Low-dose pulsatile interleukin-6 as a treatment option for diabetic peripheral neuropathy. Front Endocrinol (Lausanne). 2017;89.
30.
Pop-Russi R, Ang L, Holms C. Inflammation as therapeutic target for diabetic neuropathies. Curr Diab Res. 2016;29.
31.
Herder C, Kannenberg J, Huth C, Heier M, Püttgen M, Tonrad S, et al. Proinflammatory cytokines predict the incidence of progression of distal senso-motor polyneuropathy. KORA F4/FF4 Study. Diab Care. 2017;569–76.
32.
Lehmann H, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy update on diagnosis immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2019;981–7.
33.
He Q, Dong M, Pan Q, Wang X, Guo L. Correlation between changes in inflammatory cytokines and the combination with hypertension in patients with type 2 Diabetes Mellitus. Minerva Endocrinol. 2019;252–8.
34.
Das A, Kalra S, Tiwaskar M, Bajaj S, Seshadri K, Chowdhury S, et al. Expert Group Consensus Opinion: role of anti-inflammatory agents in the management of type 2 diabetes (T2D). J Assoc Physicians India. 2019;65–74.
35.
Dror E, Dalmas E, Meier D, Wueest S, Thevenet J, Thienel C, et al. Postrprandial macrophage-derived IL-1 stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat Immunol. 2017;283–92.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
